Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             205 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 35 Abnormal chromatin clumping in leucocytes syndrome with a high fraction of bone marrow cells in S-phase and In vitro autonomous growth Valleio, C
1997
21 1S1 p. S9
artikel
2 107 Abnormal motility patterns of neutrophils in myelodysplastic syndromes identified by image analysis Azzarà, A
1997
21 1S1 p. S28
artikel
3 132 A case of a t(1;3)(p36:q21) in chronic myelomonocytic leukemia with thrombocytosis and TPO gene expression in malignant cells Ciolli, S.
1997
21 1S1 p. S34
artikel
4 169 Aggressive chemotherapy in MDS: The Düsseldorf experience Aul, C.
1997
21 1S1 p. S45
artikel
5 196 Allogeneic bone marrow transplantation for adults with primary myelodysplastic syndrome: Evaluation of prognostic factors Shepherd, JD
1997
21 1S1 p. S52
artikel
6 163 Amifostine in low-risk and combined therapy with gemcitabine in high-risk myelodysplastic syndromes Sezer, O.
1997
21 1S1 p. S42
artikel
7 36 AML post RAEB with intense granulation alterations Rozman, M.
1997
21 1S1 p. S10
artikel
8 51 Analysis of prognostic factors for low risk myelodysplastic syndrome; a proposal of new scoring system Tomonaga, M.
1997
21 1S1 p. S14
artikel
9 170 Anti-AML chemotherapy in high-risk MDS: The M.D. Anderson cancer center experience Estey, E.
1997
21 1S1 p. S45
artikel
10 79 Antigenic characterization of bone marrow endosteal cells: A stem cell hypothesis reevaluated Walchshofer, S.
1997
21 1S1 p. S21
artikel
11 151 A patient-oriented approach to the use of erythropoietin in myelodysplastic syndromes Cazzola, Mario
1997
21 1S1 p. S39
artikel
12 101 Apoptosis and fas antigen (CD95) expression in myclodysplasia Bouscary, D.
1997
21 1S1 p. S26
artikel
13 21 Association between myelodysplastic syndromes and inflammatory bowel diseases: report of 4 new cases and review of previously reported cases Wattel, E
1997
21 1S1 p. S6
artikel
14 40 Atypical sweet's syndrome (SS) in a patient with AML secondary to a RAEB-T Pagano, L.
1997
21 1S1 p. S11
artikel
15 34 Atypical variants of MDS in children Torubarova, N.
1997
21 1S1 p. S9
artikel
16 Author index 1997
21 1S1 p. I-VIII
artikel
17 195 Autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS) Wartel, E.
1997
21 1S1 p. S52
artikel
18 9 Benzene exposure and risk of MDS/AML Smith, M.T.
1997
21 1S1 p. S3
artikel
19 77 Biological consequences of stromal abnormalities in the myelodysplastic syndrome (MDS): Its influence on the hematopoietic dysregulation Silverman, L.R.
1997
21 1S1 p. S20
artikel
20 193 BMT in MDS: The experience of the EBMT Boogaerts, Marc A.
1997
21 1S1 p. S51
artikel
21 90 Bone marrow culture studies in myelodysplastic syndromes de Souza Femandez, Teresa
1997
21 1S1 p. S24
artikel
22 192 Bone marrow transplantation for myelodysplasia: The IBMTR data Sierra, J.
1997
21 1S1 p. S51
artikel
23 200 Bone marrow transplantation in patients with myelodysplastic syndrome. A single center experience Cermak, J.
1997
21 1S1 p. S53
artikel
24 127 Both inhaled and ingested substances are involved in secondary myelodysplastic syndromes (MDS) with 6p changes Ciolli, S.
1997
21 1S1 p. S33
artikel
25 202 Calcitriol in the treatment of myelodysplastic syndromes Mellibovsky, L.
1997
21 1S1 p. S55
artikel
26 177 Carboplatin(CBDCA) alone or in combination in the treatment of acute myeloid leukema (AML) secondary to myelodysplastic syndromes and in other high risk AML Larrea, L.
1997
21 1S1 p. S47
artikel
27 102 CD34+ cells in myelodisplastic syndromes with lower percent of blasts are characterized by high spontaneus rate of apoptosis Ricciardi, M.R.
1997
21 1S1 p. S27
artikel
28 61 CFU-GM growth and survival in 258 patients with myelodysplastic syndromes Jelínek, J.
1997
21 1S1 p. S16
artikel
29 172 Chemotherapy of adult chronic myelomonocytic leukemia (CMML) Wattel, E.
1997
21 1S1 p. S46
artikel
30 188 Chemotherapy-related infections in myelodysplastic syndromes (MDS) and acute myeloid leukemia secondary to MDS (sAML). A study of 27 patients Jarque, I.
1997
21 1S1 p. S50
artikel
31 119 Childhood myelodysplasia: Cytogenetic and fish studies Mancini, M.
1997
21 1S1 p. S31
artikel
32 58 Chromosomal abnormalities in patients with myelodysplastic syndromes of low and high cytologic risk Rus, G. Pérez
1997
21 1S1 p. S16
artikel
33 112 Chromosomal abnormalities in secondary MDS/AML relationships to prior drugs and radiation Pedersen-Bjergaard, Jens
1997
21 1S1 p. S29
artikel
34 122 Chromosome 5Q31-specific DNA probe to detect intertitial long arm deletions of chromosome Bernasconi, P.
1997
21 1S1 p. S32
artikel
35 30 Chronic myelomonocytic leukemia as a secondary myelodysplasia in a chronic lymphoid leukemia case Brunel, V
1997
21 1S1 p. S8
artikel
36 28 Chronic myelomonocytic leukemia: Clinical and hematopathological features of 27 patients Marisavljevic, D.
1997
21 1S1 p. S8
artikel
37 181 Cladribine (2-CDA) is active in “high-risk”-chronic myelomonocytic leukemia and secondary or relapsed acute myelo(Mono)cytic leukemia Krieger, O.
1997
21 1S1 p. S48
artikel
38 31 Classification of chronic neutrophilic leukemia: — A report of 2 patients and review of 73 cases from the literature Ben-Tal, O.
1997
21 1S1 p. S8
artikel
39 24 Clinical and biological profile of 55 patients with Refractory Anemia with Ring Sideroblasts Richart, A.
1997
21 1S1 p. S7
artikel
40 137 Clinical potential of mutant ras Mufti, Ghulam J.
1997
21 1S1 p. S35
artikel
41 152 Clinical results of the use of different cytokines in MDS Hellström-Lindberg, Eva
1997
21 1S1 p. S39
artikel
42 120 Clonal evolution in myelodysplasic syndromes Rus, G. Pérez
1997
21 1S1 p. S31
artikel
43 71 Clonality of hematopoiesis in myelodysplasia Willemze, R.
1997
21 1S1 p. S19
artikel
44 125 Clonal karyotypic abnormalities after autologous transplantation (AT) Amigo, M.L.
1997
21 1S1 p. S32
artikel
45 2 Codification of dysmyelopoiesis in myelodysplastic syndromes Flandrin, Georges
1997
21 1S1 p. S1
artikel
46 7 Combined morphological, immunological and cytogenetic techniques in the diagnosis of myelodysplastic syndromes (MDS) Woessner, S.
1997
21 1S1 p. S2
artikel
47 50 Correlation of karyotype with clinical features and prognosis in 349 patients with MDS Haase, D.
1997
21 1S1 p. S14
artikel
48 33 Criteria for the differential diagnosis between aplastic anemia and hypocellular myelodysplasia Lorand-Metze, I.
1997
21 1S1 p. S9
artikel
49 114 Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure Stafford, DA
1997
21 1S1 p. S30
artikel
50 117 Cytogenetic and molecular study in primary myelodysplastic syndrome de Souza Fernandez, Teresa
1997
21 1S1 p. S30
artikel
51 4 Cytogenetic methods (conventional and FISH) for the study of Myelodysplastic Syndromes Jhanwar, Suresh C.
1997
21 1S1 p. S1
artikel
52 201 Cytogenetics to monitor disease outcome after allo-BMT in patients with myelodysplastic syndrome (MDS) Bernasconi, P.
1997
21 1S1 p. S53
artikel
53 116 Cytogenetic studies in 429 myelodysplastic syndromes:Prognostic value Solé, F.
1997
21 1S1 p. S30
artikel
54 126 Cytogenetic studies in secondary leukemia: Report of 28 cases from one center and comparison with the results in de novo acute myeloid leukemia (AML) Granada, I
1997
21 1S1 p. S33
artikel
55 118 Cytogenetic study and prognostic impact of complex karyotypes in 22 myelodysplastic syndromes Prieto, E.
1997
21 1S1 p. S31
artikel
56 124 Cytogenetic study of 36 patients with secondary myelodysplastic syndrome (MDS)/acute myeloid leukemia(AML) Lun˜o, E.
1997
21 1S1 p. S32
artikel
57 96 Cytokine production in vivo in mds and AML patients Preisler, H.D.
1997
21 1S1 p. S25
artikel
58 26 Cytoplasmic abnormalities of erythroblasts in a patient with refractory anaemia with ring sideroblasts Florensa, L.
1997
21 1S1 p. S7
artikel
59 108 Defective actin polymerization in neutrophils from patients with myelodysplastic syndromes Carulli, G.
1997
21 1S1 p. S28
artikel
60 109 Deficit in integrin expression on PMNs in patients with myelodyslastic syndromes Ricevuti, G.
1997
21 1S1 p. S28
artikel
61 140 Deletion of the pura gene, encoding the single-stranded DNA-binding protein purα, in myelodysplastic syndrome (MDS) and myeloid leukemias Lezon-Geyda, K.A.
1997
21 1S1 p. S36
artikel
62 129 Deletion sq- in a patient with a secondary myelodysplastic syndromes post multiple myeloma Solé, Franceac
1997
21 1S1 p. S33
artikel
63 144 Detection of telomerase activity in cell in myelodysplastic syndromes: Application of in situ telomeric repeat amplification protocol (TRAP) Ohyashiki, K.
1997
21 1S1 p. S37
artikel
64 68 Diagnostic and prognostic significance of elevated percent of fetal hemoglobin containing erythrocytes in patients with myelodysplastic syndromes Śledziowski, P.
1997
21 1S1 p. S18
artikel
65 78 Disturbed interaction between hematopoiesis and bone marrow microenvironment in myelodysplastic syndromes (MDS) Kunert, Ch.
1997
21 1S1 p. S21
artikel
66 105 DNA image cytometry in MDS bone marrow smears Widell, S.
1997
21 1S1 p. S27
artikel
67 27 Does WBC count really define two different subtypes of chronic myelomonocytic leukemia (CMML)? Analysis of a series of 119 patients Cervera, J.
1997
21 1S1 p. S7
artikel
68 131 Duplication of DER(8)t(8:12)(q12:p13) and loss of ETV6 gene in a patient with refractory anaemia Hernández, J.M.
1997
21 1S1 p. S34
artikel
69 187 Effective combined chemotherapy in children with juvenile chronic myelomonocytic leukaemia de Heredia, C. Diaz
1997
21 1S1 p. S49
artikel
70 86 Effects of rHumegakaryocyte growth and development factor (rHuMGDF) on in vitro proliferation of megakaryocyte progenitors in myelodysplastic syndromes (MDS) Fontenay-Roupie, M.
1997
21 1S1 p. S23
artikel
71 87 Effects of three new recombinant. Human GM-CSF/Erythropoietin (EPO) hybrid molecules on in vitro growth of hemopoietic progenitors in myelodysplastic syndromes (MDS) Scalzulli, P.R.
1997
21 1S1 p. S23
artikel
72 74 Enigmatic role(s) of programmed cell death (apoptosis) in myelodysplasias Yoshida, Yataro
1997
21 1S1 p. S20
artikel
73 16 Epidemiology of myelodysplastic syndromes in a French general hospital Bauduer, F.
1997
21 1S1 p. S5
artikel
74 83 Erythropoiesis, erythrokinetics and erytrocytokinetics in myelodysplastic syndromes Lipsic, T.
1997
21 1S1 p. S22
artikel
75 110 Established chromosome changes in myelodysplastic syndromes Van den Berghe, H.
1997
21 1S1 p. S29
artikel
76 97 Expression of CD36 (GPIIIb) on platelets in MDS Neuwirtová, R.
1997
21 1S1 p. S25
artikel
77 104 Expression of CD34, P170, and apoptosis-controlling proteins (BCL-2, BAX, BCL-X, BAD, ICE and CPP32) in myelodysplastic syndromes Campos, L.
1997
21 1S1 p. S27
artikel
78 100 Expression of FAS/APO-1/CD95 antigen and its function in myelodysplastic syndromes Lepelley, P.
1997
21 1S1 p. S26
artikel
79 99 Expression of LRP and its correlation with other drug resistance proteins and outcome in myelodysplastic syndromes (MDS) Lepelley, P.
1997
21 1S1 p. S26
artikel
80 98 Expression of the myeloid antigens on bone marrow cells in patients with myelodisplastic syndromes Masljak, Z.
1997
21 1S1 p. S26
artikel
81 103 Extensive apoptosis of CD34+ marrow cells in patients with mds is related to low colony forming cell number and probably to hematopoietic deficiency Kourakli-Symeonidis, A.
1997
21 1S1 p. S27
artikel
82 22 Familial myelodysplastic syndromes: A key to understanding leukaemogenesis? Mijovic, A.
1997
21 1S1 p. S6
artikel
83 91 Ferrokinetic studies in myelodysplasia suggests a dissociation of proliferation and differentiation in erythropoiesis Brada, S.
1997
21 1S1 p. S24
artikel
84 182 Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of refractory anemia with excess of blasts in transformation (RAEB-t) Ferrara, F.
1997
21 1S1 p. S48
artikel
85 161 G-CSF treatment after intensive chemotherapy in high risk myelodysplastic syndromes (MDS) or acute leukemia (AL) evolving from MDS: A randomized study Bernasconi, C.
1997
21 1S1 p. S42
artikel
86 11 Glutathione S transferase theta 1 (GSTT1) gene defects in myelodysplastic syndromes (MDS) and their correlation with Kryotype and exposure to potential carcinogens Preudhomme, C.
1997
21 1S1 p. S3
artikel
87 60 Hematologic, histologic, cytogenetic, and survival analysis of 60 patients with primary myelodysplastic syndromes (MDS) Souza, J.M.
1997
21 1S1 p. S16
artikel
88 81 Hemopoietic microenvironment in refractory anemia with increased number of blasts (RAEB) Rugal, V.
1997
21 1S1 p. S21
artikel
89 199 Hemopoietic progenitor cells transplantation from HLA-identical siblings for myelodysplasia: Outcome of 11 patients from a single institution Martínez, C.
1997
21 1S1 p. S53
artikel
90 23 Heterogeneity of acquired idiopathic sideroblastic anemia (AISA): Results of a prospective follow-up study in 189 patients Aul, C.
1997
21 1S1 p. S6
artikel
91 139 Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome C oxidase in two patients with acquired idiopathic sideroblastic anaemia Gattermann, N.
1997
21 1S1 p. S36
artikel
92 37 High peripheral but low marrow blasts: Myelodysplastic syndrome or peripheral acute leukemia? Ündar, B.
1997
21 1S1 p. S10
artikel
93 171 Idarubicin, fludarabine, cytarabine and G-CSF (FLAG-IDA) for the treatment of high risk MDS or AML Parker, J.E.
1997
21 1S1 p. S45
artikel
94 85 Identification of a group of thrombocytopenic MDS patients. Candidate for in vivo treatment with PEG-rHuMGDF Fontenay-Roupie, M.
1997
21 1S1 p. S22
artikel
95 73 Immumophenotyping in MDS del Can˜izo, M.C.
1997
21 1S1 p. S19
artikel
96 70 Immunology of MDS, towards a DNA vaccine Hamblin, TJ
1997
21 1S1 p. S19
artikel
97 165 Immunotherapy with low-dose interleukin-2 in patients with myelodysplastic syndromes RAEB and RAEB-T (an ongoing pilot study) Faber, E.
1997
21 1S1 p. S43
artikel
98 59 Impact of advanced age on the prognostic value of karyotype and scoring systems in primary myelodysplastic syndromes (p-MDS) Parlier, V.
1997
21 1S1 p. S16
artikel
99 48 Impact of histopathology on diagnosis, clinics and outcome of myelodysplastic syndromes Georgii, A.
1997
21 1S1 p. S13
artikel
100 20 Incidence of cancer and body iron stores in sideroblastc anemia Sˇisˇková, M.
1997
21 1S1 p. S6
artikel
101 10 Increasing incidence of MDS: Real or fictitious? Aul, C.
1997
21 1S1 p. S3
artikel
102 176 Induction of complete hematological and cytogenic remissions in myelopysplastic syndromes and CMML by topotecan Baran, M
1997
21 1S1 p. S47
artikel
103 189 Infectious complications after intensive remission induction in advanced myelodysplastic syndromes and de novo acute myeloid leukemia Böhme, A.
1997
21 1S1 p. S50
artikel
104 186 Intensive antileukemic treatment and/or allogeneic or autologous bone marrow or PBSC transplantation in myelodysplastic syndromes and in post-MDS acute myeloid leukaemia Finelli, C.
1997
21 1S1 p. S49
artikel
105 174 Intensive chemotherapy (idarubicin, ARA-C, VP-16) combined with G-CSF-priming yields high remission rates in patients with advanced MDS and high-risk AML Ganser, A.
1997
21 1S1 p. S46
artikel
106 184 Intensive chemotherapy in de novo MDS. Outcome of patients who achieved partial remission (PR) Wattel, E.
1997
21 1S1 p. S49
artikel
107 173 Intensive chemotherapy with quinine in myelodysplastic syndromes (MDS) Fenaux, P.
1997
21 1S1 p. S46
artikel
108 153 Interleukin 3 (IL-3) and newer hematopoietic growth factors in the management of myelodysplastic syndrome (MDS) Saba, Hussain I.
1997
21 1S1 p. S40
artikel
109 84 In vitro effect of c-mpl-ligand on CD34 positive cells isolated from patients with chronic myelodysplastic syndromes (MDS) Hofmann, W.-K.
1997
21 1S1 p. S22
artikel
110 133 Karyotype studies in patients with myelodysplastic syndromes Salamantchouk, Z.
1997
21 1S1 p. S34
artikel
111 1 Laboratory presentation and morphological characteristics of myelodysplastic syndromes Vallespí, Teresa
1997
21 1S1 p. S1
artikel
112 156 Lenograstim associated or not to ARA-C (3mg/m2X2) as therapy for poor prognosis refractory anemia with excess of blasts (RAEB) Chomienne, C.
1997
21 1S1 p. S40
artikel
113 63 Leukemic risk im patients aged less than 60 years with myelodysplastic syndromes (MDS): A multivariate analysis of prognostic factors in 140 patients Sanz, G.F.
1997
21 1S1 p. S17
artikel
114 43 Leukemoid reaction mimicking acute promyelocytic leukemia in a patient with myelodysplastic syndrom Carral, A.
1997
21 1S1 p. S11
artikel
115 185 Long term survival after intensive chemotherapy in de novo MDS: Lille's experience Debotton, S.
1997
21 1S1 p. S49
artikel
116 158 Long term treatment of intermediate risk myelodys-plastic syndrome with rhG-CSF and rhEPO: Interim report of an ongoing randomized phase III trial Lentini, G.
1997
21 1S1 p. S41
artikel
117 160 Low-dose Ara-C and G,M-CSF in high-risk myelodysplastic syndromes and acute leukaemia of the old Sastre, JL
1997
21 1S1 p. S41
artikel
118 175 Low dose 5-AZA-′2-deoxycytidine in eldery patients with high risk MDS Wijermans, P.
1997
21 1S1 p. S46
artikel
119 168 Low-dose chemotherapy in MDS Hellström-Lindberg, Eva
1997
21 1S1 p. S45
artikel
120 88 Low stem cell factor plasma levels are correlated with in vitro leukemic growth in myelodysplastic syndromes Cortelezzi, A.
1997
21 1S1 p. S23
artikel
121 106 Mast cell (MC) lineage involvement in myelo-dysplastic syndromes: Diagnostic utility of tryptase staining Valent, P.
1997
21 1S1 p. S28
artikel
122 82 Megakaryopoiesis in myelodysplastic syndromes: Morphological and immunocytochemical features Lorand-Metze, I.
1997
21 1S1 p. S22
artikel
123 203 Molecular biology of elderly AML and its relationship to myelodysplasia (MDS) Willman, Cheryl L.
1997
21 1S1 p. S55
artikel
124 136 Molecular biology of elderly AML and its relationship to myelodysplasia (MDS) Willman, Charyl L
1997
21 1S1 p. S35
artikel
125 141 Molecular definition of two narrow interval at 7q22.1 and 7Q34 associated with myelodysplasia Cotter, F.E.
1997
21 1S1 p. S36
artikel
126 135 Molecular genetics of myeloid disorders characterized by −7/del(7q) Shannon, K.
1997
21 1S1 p. S35
artikel
127 134 Molecular mapping of the DEL(5Q) in myelodysplastic syndromes Le Beau, M.M.
1997
21 1S1 p. S35
artikel
128 113 Morphological, cytogenetic, molecular and etiological features of the ≪ 17p syndrome ≫ in MDS Preudhomme, C.
1997
21 1S1 p. S29
artikel
129 18 Morphological features of myelodysplasia after autologous transplantation Amigo, M.L.
1997
21 1S1 p. S5
artikel
130 62 Multivariate analysis of prognostic factors for survival in 140 patients aged less than 60 years with myelodysplastic syndromes (MDS) Sanz, G.F.
1997
21 1S1 p. S17
artikel
131 138 Mutant RAS or FMS confer abnormal growth in haematopoietic cells: Poor clinical outcome in myelodysplasia with RAS, FMS and p53 mutations Padua, R.A.
1997
21 1S1 p. S36
artikel
132 145 Mutations of the MSH2 gene in myelodysplastic syndrome (MDS) Duthoit, E.
1997
21 1S1 p. S37
artikel
133 57 Myelodisplastic syndromes prognostic factors in 133 patients with cytogenetic study Rus, G. Pérez
1997
21 1S1 p. S15
artikel
134 19 Myelodysplastic syndrome after autologous stem cell transplantation Laurenti, L.
1997
21 1S1 p. S5
artikel
135 147 Myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria; phenotypic and molecular search for an association Iwanaga, M.
1997
21 1S1 p. S38
artikel
136 121 Myelodysplastic syndrome and 17P deletion Stamatoullas, A.
1997
21 1S1 p. S31
artikel
137 39 Myelodysplastic syndrome and thrombotic thrombocytopenic purpura Ündar, L.
1997
21 1S1 p. S10
artikel
138 45 Myelodysplastic syndrome in its fibrotic variant: A borderline to chronic myeloproliferation Wilezak, W.
1997
21 1S1 p. S12
artikel
139 148 Myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) supervening previously untreated chronic B-lymphocytic leukemia (B-cll): Demonstration of the concomitant presence of two different malignant clones by immunologic and molecular analysis Schwarzmeier, J.D.
1997
21 1S1 p. S38
artikel
140 194 Myelodysplastic syndrome or leukemia developing after MDS treated by allogeneic bone marrow transplantation: Outcome of 90 adult patients Alessandrino, E.P.
1997
21 1S1 p. S52
artikel
141 17 Myelodysplastic syndromes in Thailand: A retrospective pathologic and clinical analysis of 117 cases Intragumtornchai, Tanin
1997
21 1S1 p. S5
artikel
142 64 Myelodysplastic syndromes (MDS) in patients aged>20 and <40 years Latagliata, R.
1997
21 1S1 p. S17
artikel
143 44 Myelodysplastic syndromes with bundles of Auer rods. Study of two cases Domingo-Claros, A
1997
21 1S1 p. S12
artikel
144 123 Neutrophil dysplasia is not a feature of the abnormal chromosomal clones in myelodysplastic syndromes Hast, R.
1997
21 1S1 p. S32
artikel
145 115 New biological insights into chromosome 21 rearrangements in the myelodysplastic syndrome (MDS) Naifeld, V.
1997
21 1S1 p. S30
artikel
146 38 Nodular lesions of monocytic component in myelodysplastic syndrome (MDS) Mongkonsritragoon, W.
1997
21 1S1 p. S10
artikel
147 157 Non-clonal response to erythropoietin in myelodysplastic syndromes Eriksson, M.
1997
21 1S1 p. S41
artikel
148 12 Occupational and environmental exposures and the myelodysplastic syndromes: A case-control study West, RR
1997
21 1S1 p. S4
artikel
149 15 Occupational and environmental risk factors of MDS = a case control study Nisse, C.
1997
21 1S1 p. S4
artikel
150 178 Oral idarubicin administration as monochemotherapy in myelodisplastic syndromes Petrini, M.
1997
21 1S1 p. S47
artikel
151 198 Outcome of bone marrow transplantation in myelodysplastic syndrome or secondary acute myeloid leukemia Lorand-Metze, I
1997
21 1S1 p. S53
artikel
152 146 Oxidative DNA damage and low reduced glutathione concentration is associated with elevated tumor necrosis factor alpha concentration in myelodysplasia Bowen, D.
1997
21 1S1 p. S38
artikel
153 143 Patterns of expression of RAS, P53 and MDM2 proteins in myelodysplastic syndromes Silva, E.S.
1997
21 1S1 p. S37
artikel
154 13 Pediatric myelodysplasia: Characteristics and prognostic factors Ortega, Juao J.
1997
21 1S1 p. S4
artikel
155 80 Phenotypic analysis of endosteal cells in myelodysplastic syndromes and other hemopoietic disorders Sillaber, C.
1997
21 1S1 p. S21
artikel
156 94 Plasma thrombopoietin (TPO) level in patients with myelodysplastic syndromes (MDS) Ogata, K.
1997
21 1S1 p. S25
artikel
157 130 Polysomy for a 20q- chromosome masked by multiple markers in a case of secondary MDS Falzetti, D.
1997
21 1S1 p. S34
artikel
158 162 Potential for use of amifostine in the treatment of poor prognosis acute myelogenous leukemia Preisler, H.D.
1997
21 1S1 p. S42
artikel
159 5 Primary chromosomal abnormalities in myelodysplastic syndromes (MDS) Mecucci, Cristina
1997
21 1S1 p. S2
artikel
160 54 Primary myelodysplastic syndromes : A retrospective study of treatment response and prognostic features in 39 patients in the western region of Algeria Bekadja, M.A
1997
21 1S1 p. S15
artikel
161 52 Primary myelodysplastic syndromes: Multivariate analysis of prognostic factors in Brazilian patients Velloso, E.R.P.
1997
21 1S1 p. S14
artikel
162 14 Problems in the classification of CMML. Dysplastic vs profliferative type Germing, U.
1997
21 1S1 p. S4
artikel
163 55 Prognosis in myelodysplastic syndromes with specific reference to karyotypes — Experience on 296 patients from a single institution Pfeilstöcker, M.
1997
21 1S1 p. S15
artikel
164 47 Prognostic factors in younger patients with myelodysplastic syndromes (MDS) Sanz, G.F.
1997
21 1S1 p. S13
artikel
165 56 Prognostic impact of cytogenetic investigations in 270 patients with primary myelodysplastic syndromes Germing, U.
1997
21 1S1 p. S15
artikel
166 66 Prognostic significance of serum protein electrophoresis pattern changes in patients with myelodysplastic syndromes Symeonidis, A.
1997
21 1S1 p. S18
artikel
167 29 Proliferative chronic myelomonocytic leukemia (P-CMML) emerging after splenectomy in two patients with dysplastic CMML (D-CMML) Vallespí, Teresa
1997
21 1S1 p. S8
artikel
168 164 Promising cyclosporin a therapy for myelodysplastic syndrome Jonásˇová, A.
1997
21 1S1 p. S42
artikel
169 179 Promotion of multilineage hematopoiesis in patients with myelodysplastic syndrome: A phase I/II clinical trial with amifostine List, A.
1997
21 1S1 p. S47
artikel
170 142 5q- Syndrome: Breakpoint investigation Abdelhay, Eliana
1997
21 1S1 p. S37
artikel
171 154 Quality of life in persons with myelodysplastic syndromes: The neglected variable Thomas, Mary Laudon
1997
21 1S1 p. S40
artikel
172 111 Recent and new characteristic chromosome abnormalities in myelodysplastic syndromes (MDS) Mecucci, Cristina
1997
21 1S1 p. S29
artikel
173 46 Recent developments in the prognostic classification for MDS: Results of The International Risk Analysis Workshop Greenberg, P.
1997
21 1S1 p. S13
artikel
174 72 Recruitment and identification of “normal” hematopoietic cells in MDS Frassoni, F
1997
21 1S1 p. S19
artikel
175 25 Refractory anemia, pure sideroblastic anemia and refractory cytopenia with multilineage dysplasia Rus, G. Pérez
1997
21 1S1 p. S7
artikel
176 42 Refractory thrombocytopenia with bone marrow dysplasia: MDS or another entity? Ündar, B.
1997
21 1S1 p. S11
artikel
177 183 Results of treatment in patients with acute myeloid leukemia preceeded by primary myelodysplastic syndrome Urbańska-Ryś, H.
1997
21 1S1 p. S48
artikel
178 32 Review of 100 cases considered like MDS by clinicians Tassin, F.
1997
21 1S1 p. S9
artikel
179 159 r-hu-Epo and G-CSF treatment in simple and sideroblastic refractory anemias: A multicenter study Remacha, A
1997
21 1S1 p. S41
artikel
180 95 Serum levels of thrombopoietin (TPO) In myelodysplasias Fontenay-Roupie, M.
1997
21 1S1 p. S25
artikel
181 128 Single del(11q) in a patient with RAEB which progressed to erythroleukemia Martinez-Climent, J.A.
1997
21 1S1 p. S33
artikel
182 69 Spontaneous improvement of hematological parameters in 8 patients with myelodysplastic syndromes (MDS) Breccia, M.
1997
21 1S1 p. S18
artikel
183 92 Stem cell defect and the genesis of cytopenias in myelodysplastic syndromes (MDS) and their correction by amifostine Raza, A.
1997
21 1S1 p. S24
artikel
184 155 Successful anti-cytokine based approach to treat myelodysplastic syndromes (MDS) Raza, A.
1997
21 1S1 p. S40
artikel
185 53 Survival analysis of 60 patients with primary myelodysplastic syndromes (MDS) according to prognostic groups defined by Mufti (1992) Souza, J.M.
1997
21 1S1 p. S14
artikel
186 65 Survival and outcome in 30 patienta with chronic myelomonocytic leukemia (CMML) Shtarlid, M.
1997
21 1S1 p. S17
artikel
187 41 Sweet's Syndrome in neutropenic patient with myelodysplasia Niero-Melo, L
1997
21 1S1 p. S11
artikel
188 167 Tamoxifen as treatment for myelodysplastic syndromes? — A case report Uhr, M.
1997
21 1S1 p. S43
artikel
189 190 T-cell depleted (SBA-E-) bone marrow transplantation for myelodysplastic syndromes Castro-Malaspina, H.
1997
21 1S1 p. S51
artikel
190 75 Telomere dynamics in myelodysplastic syndromes Toyama, K.
1997
21 1S1 p. S20
artikel
191 76 The absolute number of CD34+ cells and CD34+ cells in S-phase increase during the evolution of myelodysplastic syndromes (MDS) Span, L.
1997
21 1S1 p. S20
artikel
192 93 The combination of all-trans retinoic acid (atra) and bryostatin 1 (BRYO) induces monocytic differentation (MD) In human myeloid leukemia Stone, R.
1997
21 1S1 p. S24
artikel
193 180 The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes Vasilica, M.
1997
21 1S1 p. S48
artikel
194 3 The F.A.B. classification of the myelodysplastic syndromes (MDS) Bennett, J.M.
1997
21 1S1 p. S1
artikel
195 8 The history of MDS: The role of the F.A.B. classification and the development of risk assessment Bennett, John M.
1997
21 1S1 p. S3
artikel
196 49 The influence of cytogenetic abnormalities on treatment outcome after intensive antileukemic therapy for patients with high risk MDS De Witte, T.
1997
21 1S1 p. S13
artikel
197 6 The 5q- syndrome Van den Berghe, H.
1997
21 1S1 p. S2
artikel
198 191 The seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS) Anderson, J.E.
1997
21 1S1 p. S51
artikel
199 89 The value of cell cultures for diagnosis of mixed myelodysplastic syndromes/ myelopro-liferative disorders del Can˜izo, M.C.
1997
21 1S1 p. S23
artikel
200 197 t(3;5) High-grade myelodysplasia and acute myeloid leukemia of young adults responds favorably to allogeneic bone marrow transplantation Arber, D.A.
1997
21 1S1 p. S52
artikel
201 67 Thrombocytosis and sideroblastic anaemia Ancin, I.
1997
21 1S1 p. S18
artikel
202 150 Treatment of low-risk MDS: Combination of hematopoietic growth factors and biological response modifiers Hoelzer, D.
1997
21 1S1 p. S39
artikel
203 166 Treatment of multiple transfused patients with myelodysplastic syndromes by iron chelation with desferrioxamine Jensen, P.D.
1997
21 1S1 p. S43
artikel
204 149 Treatment strategies in MDS: Who and how should be treated? Mufti, Ghulam J.
1997
21 1S1 p. S39
artikel
205 204 Trilineage myelodysplasia in patients with acute myeloid leukaemia correlates with shorter disease free and overal survival Staneva, M.
1997
21 1S1 p. S55
artikel
                             205 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland